References
- Center for Drug Evaluation and Research . Guidance for industry diabetes mellitus: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008; cited 2016 Sep 30 . http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf
- European Medicines Agency . Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. cited 2016 Sep 30. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256.pdf
- Patil HR , Al Badarin FJ , Al Shami HA , et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol. 2012;110(6):826–833.
- Monami M , Ahrén B , Dicembrini I , et al. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013;15(2):112–120.
- Engel SS , Golm GT , Shapiro D , et al. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol. 2013;12:3.
- McInnes G , Evans M , Del Prato S , et al. Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients. Diabetes Obes Metab. 2015;17(11):1085–1092.
- Iqbal N , Parker A , Frederich R , et al. Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials. Cardiovasc Diabetol. 2014;13:33.
- White WB , Pratley R , Fleck P , et al. Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15(7):668–673.
- Rosenstock J , Marx N , Neubacher D , et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol. 2015;14:57.
- Scirica BM , Bhatt DL , Braunwald E , et al. Saxagliptin and cardiovascular outcomes in patientswith type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326.
- White WB , Cannon CP , Heller SR , et al. EXAMINE:alogliptinafter acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–1335.
- Green JB , Bethel MA , Armstrong PW , et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–242.
- Monami M , Dicembrini I , Mannuci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2014;24(7):689–697.
- Wu S , Hopper I , Skiba M , et al. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants. Cardiovasc Ther. 2014;32(4):147–158.
- Weir DL , McAlister FA , Senthilselvan A , et al. Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study. JACC Heart Fail. 2014;2(6):573–582.
- Kim C , Glynn RJ , Liu J , et al. Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study. Acta Diabetol. 2014;51(6):1015–1023.
- Yu OH , Filion KB , Azoulay L , et al. Incretin-based drugs and the risk of congestive heart failure. Diabetes Care. 2015;38(2):277–284.
- Scirica BM , Braunwald E , Raz I , et al.; SAVOR-TIMI 53 Steering Committee and Investigators . Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014; 130(18):1579–1588.
- Briefing Material . NDA 22350: saxagliptin (Onglyza). NDA 200678: saxagliptin/Metformin (Kombiglyze XR). April 2015; cited 2016 Sep 30 . http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolic-DrugsAdvisoryCommittee/UCM442060.pdf
- EMDAC Briefing Document Cardiovascular Outcomes Trial EXAMINE/NDAs 022271, 022426, & 203414 Nesina (alogliptin), Oseni (alogliptin/pioglitazone), & Kazano (alogliptin/metforminHCl). 2015; cited 2016 Sep 30 . http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM442062.pdf
- Zannad F , Cannon CP , Cushman WC , et al. Heart failure and mortality outcomes on alogliptin versus placebo from the EXAMINE trial. Lancet. 2015;385:2067–2076.
- McGuire DK , Van Dewerf F , Armstrong PW , et al.; Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group . Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of arandomized clinical trial. JAMA Cardio. 2016; 1(2):126–135.
- Scirica BM. The safety of dipeptidyl peptidase 4 inhibitors and the risk for heart failure. JAMA Cardiol. 2016;1(2):123–125.
- cited Sep 30, 2016. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM493965.pdf
- McMurray JJ , Ponikowksi P , Bolli GB , et al. Vildagliptin in Ventricular Dysfunction Diabetes Trial (VIVIDD). Eur J Heart Fail. 2013;12 (suppl):1.
- https://clinicaltrials.gov/ct2/show/NCT01897532
- Marx N , Rosenstock J , Kahn SE , et al. Design and baseline characteristics of the CARdiovascular outcome trial of LINAgliptin versus glimepiride in type 2 diabetes (CAROLINA®). Diab Vasc Dis Res. 2015;12(3):164–174.
- Salsali A , Kim G , Woerle HJ , et al. Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials. Diabetes Obes Metab. 2016;18(10):1034–1040.
- cited 2016 Sep 30. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334550.pdf
- Sonesson C , Johansson PA , Johansson E , et al. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol. 2016;15:37.
- Zinman B , Wanner C , Lachin JM , et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
- Ratner R , Han J , Nicewarner D , et al. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol. 2011;10:22.
- MacConell L , Gurney K , Malloy J , et al. Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients. Diabetes Metab Syndr Obes. 2015;18(8):241–253.
- cited 2016 Sep 30 www.sanofi.co.uk/l/gb/en/download.jsp?file=1B4E8D41-8F6C-4399-8C64…pdf
- Caterson ID , Bain SC , Gross J , et al. Cardiovascular safety of liraglutide: pooled analysis of major adverse cardiovascular events across weight management and type 2 diabetes development programs. Circulation. 2015;132(Suppl_3/A12630).
- Ferdinand KC , Botros FT , Atisso CM , et al. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol. 2016 Feb 24;15:38.
- Fisher M , Petrie MC , Ambery PD , et al. Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. Lancet Diabetes Endocrinol. 2015;3(9):697–703.
- Pfeffer MA , Claggett B , Diaz R , et al. ELIXA Investigators . Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–2257.
- Marso SP , Daniels GH , Brown-Frandsen K , et al. LEADER Investigators . Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.
- Marso SP , Bain SC , Consoli A , et al.; SUSTAIN-6 Investigators . Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844.
- 2016 Sep 30. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM508422.pdf
- Margulies KB , Hernandez AF , Redfield MM , et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016;316(5):500–508.
- Jorsal A . Effect of liraglutide, a glucagon-like peptide-I analogue, on left ventricular function in chronic heart failure patients with and without diabetes: the LIVE study. Eur Soc Cardiol (ESC) Heart Fail. 2016;cited 2016 May 22 . Presentation 599. Florence, Italy
- https://clinicaltrials.gov/ct2/show/NCT02918591
- https://clinicaltrials.gov/ct2/show/NCT02862067
- https://clinicaltrials.gov/ct2/show/NCT02728453
- https://clinicaltrials.gov/ct2/show/NCT02653482
- Faillie JL , Yu OH , Yin H , et al. Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus. JAMA Intern Med. 2016;176(10):1474–1481.
- Zhang L , Krzentowski G , Albert A , et al. Risk of developing retinopathy in diabetes control and complications trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care. 2001;24(7):1275–1279.
- Ferrannini G , Hach T , Crowe S , et al. Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38:1730–1735.
- Frías JP , Guja C , Hardy E , et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016 Sep 15; pii: S2213-8587(16)30267-4. Epub ahead of print. 10.1016/S2213-8587(16)30267-4